NCT07567313Not yet recruitingPhase 4
Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy
Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study of Patients With Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
This study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoembolization for stage IV lung squamous cell carcinoma.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 166 (estimated)
- First submitted
- 2 Apr 2026
- Start date
- 20 Apr 2026
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Lung cancer
- NCT number
- NCT07567313
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 166
- From 20 Apr 2026 to the primary completion date, 1 Jan 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;
Other illness
- Have a history of allergy to contrast agents or chemotherapy drugs;
- Hypertension patients still have poor blood pressure control (systolic blood pressure \> \>160mmHg, diastolic blood pressure \> 100 mmhg) after antihypertensive drugs treatment;
- Have a history of mental illness or psychotropic drug abuse;
- Patients with autoimmune diseases;
Lab values
- There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;
- Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);
Other
- Coagulation function is seriously abnormal and cannot be corrected;
- Pregnant or lactating female patients;
- Patients with symptomatic brain metastasis;
Who the study is looking for
- Squamous cell carcinoma of the lung confirmed by histology or cytology;
- According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.
- Has received standard first-line chemotherapy immunotherapy for 4\~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;
- The patient is 18-80 years old;
- ECOG PS score is 0-1;
- The main organ functions meet the following criteria: (1) Blood routine examination: hemoglobin (HB) ≥ 90g/L; Leukocyte (ANC) ≥ 3.0× 109/L; Neutrophils ≥ 1.5× 109/L; Platelet (PLT) ≥ 75× 109/L; (2) Biochemical examination: albumin (ALB)≥29g/L; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2uln; Total bilirubin (TBIL) ≤ 1.5 ULN; Creatinine ≤ 1.5 ULN;
- Patients and/or their families agree to participate in clinical trials and sign informed consent forms;
- No history of other malignant tumors;
- No active infection;
- Be able to cooperate with research follow-up;
- At least one measurable lesion (according to RECIST 1.1);
- The expected survival time is more than 3 months.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.